格隆汇2月10日丨医渡科技(02158.HK)公告，2月10日耗资1万港元回购1700股。 ...

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的 ...

Market Overview - The Hong Kong stock market showed initial gains but narrowed its increase, with the Hang Seng Index closing up 0.58% above 27,000 points, while the Hang Seng China Enterprises Index and Hang Seng Tech Index rose by 0.81% and 0.62% respectively [1][2]. Sector Performance - Technology stocks rebounded, driven by AI application stocks, with the stock of Reading Group surging over 15%. The film and entertainment sector remained active, and the biopharmaceutical sector saw widespread gains, led by Fuhong Hanlin [3][4]. - New consumption concept stocks, paper industry stocks, home appliance stocks, shipping stocks, and automotive stocks mostly increased. Conversely, education stocks faced declines, with gaming stocks collectively sluggish, and real estate, gas, electric, and telecom stocks also underperformed [3][4]. Notable Stocks - AI application stocks saw significant gains, with Reading Group rising 15.41%, and Zhiyun up 14.81%, reaching a new historical high during the session. Other stocks like Fubo Group and Yidu Technology also experienced increases [6][8]. - In the film sector, Orange Sky Entertainment rose over 7%, with other companies like Damai Entertainment and Ningmeng Film also following suit [10]. - The biopharmaceutical sector was buoyed by Fuhong Hanlin's increase of over 7%, with other companies like WuXi Biologics and WuXi AppTec also seeing gains [12]. Industry Insights - The real estate sector faced pressure, with Shimao Group dropping over 6% amid ongoing sales challenges in the industry. Major real estate companies are reportedly initiating organizational restructuring [13][14]. - Education stocks struggled, with Guangzheng Education falling over 5%, alongside declines in New Oriental and other educational institutions [15]. Investment Outlook - According to Everbright Securities, the current liquidity environment in the Hong Kong stock market is entering an observation period, with limited space for further tightening. Positive catalysts could lead to a recovery in market sentiment and capital inflow [22].

港股市场回购统计周报 2026.02.02-2026.02.08 | 分析师： | 刘景锋 | | | --- | --- | --- | | 中央编号： | BXJ117 | | | 联系电话： | 852-6222 | 4563 | | 邮箱： | liujingfeng@cnzsqh.hk | | 1 目录 2 l 港股市场回购周统计数据 l 上市公司回购的意义与作用 港股市场回购周统计数据 3 港股市场回购周统计数据（2026.02.02-2026.02.08） l 周回购数据总汇 | 证券代码 | 证券简称 | 期间回购金额 | 期间回购数量 | 回购数量占 | | --- | --- | --- | --- | --- | | | | (万港元) | (万股) | 总股本比例 | | 2057.HK | 中通快递-W | 326,936.30 | 1,825.44 | 2.29% | | 1810.HK | 小米集团-W | 48,588.93 | 1,405.00 | 0.05% | | 3888.HK | 金山软件 | 8,998.77 | 327.56 | 0.23% | | 0175.HK ...

Market Performance - The Hong Kong stock market indices initially rose but later narrowed their gains, with the Hang Seng Index closing up 0.58%, maintaining above 27,000 points [1] - The Hang Seng China Enterprises Index and the Hang Seng Tech Index increased by 0.81% and 0.62% respectively [1] Sector Highlights - Technology stocks in Hong Kong rebounded, driven by a recovery in U.S. tech stocks after a significant drop influenced by AI developments, with Alibaba and JD.com rising approximately 2% [1] - Other tech companies such as NetEase, Xiaomi, and Baidu also saw gains, while the AI video revolution led by Seedance 2.0 resulted in a more than 15% increase for China Literature [1] - Biopharmaceutical stocks performed strongly, with a focus on leading companies in the innovative drug industry, particularly Huadong Medicine leading the sector [1] - New consumption concept stocks, paper industry stocks, home appliance stocks, shipping stocks, and automotive stocks mostly rose [1] Underperforming Sectors - The education sector experienced significant declines, while gaming stocks that had performed well previously showed collective weakness [1] - Nationally listed real estate companies are expected to report losses exceeding 200 billion, leading to a general decline in property stocks [1] - Gas, electricity, and telecommunications stocks also showed poor performance [1]

Group 1 - Multiple Hong Kong AI medical concept stocks showed active performance on February 10, with Yunzhisheng rising by 11.64%, Inspur Intelligent by 9.46%, Yidu Tech by 2.94%, and Jingtai Holdings by 2.66% [1] - Yunzhisheng announced on February 9 that it completed the placement of 1.008 million new H-shares, accounting for approximately 2.32% of the total issued H-shares and 1.38% of the total issued shares after the placement [3] - The placement price for each H-share was set at HKD 310, with net proceeds from the placement amounting to approximately HKD 307 million, of which about 65% will be used for core technology research and development [3]

Core Insights - The project aims to establish a high-quality, standardized multimodal database for gastrointestinal tumors, focusing on enhancing early detection rates and treatment precision in China [2][3][4] Group 1: Project Overview - The initiative is led by Professor Liao Jiazhi from Tongji Hospital, with a core team comprising experts from various medical and data science fields [3] - The project will integrate diverse data types, including endoscopic images, pathology slides, genetic sequencing, and clinical follow-ups, to create a comprehensive data asset for gastrointestinal tumors [4] Group 2: Technological Framework - The core technology of the project revolves around "multimodal" and "standardization," aiming to improve the efficiency of AI product and technology development in gastrointestinal oncology [4] - The collaboration plans to gather and manage tens of thousands of high-quality case data during the project period, developing AI algorithms for early screening, precise classification, efficacy prediction, and recurrence risk assessment [4] Group 3: Industry Impact - The partnership between Yidu Technology and Tongji Hospital represents a practical application of the "clinical demand-driven, AI-powered research, and industry-academia collaboration" model, which is expected to enhance the overall diagnostic and treatment levels for gastrointestinal tumors in China [5] - Yidu Technology has extensive experience in data governance and multimodal analysis, having processed nearly 7 billion authorized medical records across over 10,000 hospital partnerships by September 30, 2025 [5]

Group 1 - The project aims to build a high-quality, standardized data platform for the entire cycle of gastrointestinal tumor diagnosis and treatment, developing an AI-assisted diagnostic system to improve early detection rates and treatment precision in China [2][3] - The initiative is part of a national mechanism to accelerate key core technology breakthroughs and promote the transformation of scientific achievements in the healthcare sector [3] - The project is led by a core clinical and research team from Tongji Hospital, supported by Yidu Technology, focusing on integrating multimodal data to enhance AI-driven diagnostic processes [3][4] Group 2 - The technology core of the project is based on "multimodal" and "standardization," aiming to create a comprehensive, high-quality gastrointestinal tumor data asset library that enhances the efficiency of AI product development [4] - The collaboration plans to gather and govern tens of thousands of high-quality case data, developing AI algorithms for early screening, precise classification, efficacy prediction, and recurrence risk assessment [4] - The project will also establish clinical application guidelines and industry standards for AI in gastrointestinal tumor diagnosis and treatment, fostering the development of professionals with both clinical and data science expertise [4][5] Group 3 - Yidu Technology has extensive experience in data governance and multimodal analysis, having served 127 well-known medical institutions and processed nearly 7 billion authorized medical records by September 30, 2025 [5] - The collaboration represents a practical application of an innovative model driven by clinical needs and AI development, aiming to enhance the overall diagnostic level for gastrointestinal tumors in China [5] - The project is expected to contribute to the "Healthy China 2030" initiative by establishing data governance standards and AI development pathways that can be replicated in other major disease areas [5]

Core Viewpoint - The company, Yidu Tech (02158), is actively repurchasing shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback, repurchasing 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the company's eleventh consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing offering "Yidu Qianyu" demonstrate solid technical capabilities, performing well in accuracy and traceability of medical evidence in tests conducted by Citigroup [1] - The company is positioned in the first tier alongside leading products like Ant Group's "Alfu" and iFlytek's "Xiao Yi," creating a synergistic layout between its To-G (government and hospital) and To-C (consumer) business segments [1]

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback of 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the 11th consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing "Yidu Qianyu" demonstrate solid technical capabilities, ranking alongside leading products in accuracy and traceability of medical evidence [1]